AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

BioMidwest

AbbVie Continues Charitable Giving, Donates $50 Million to St. Jude

Christmas came a little early for St. Jude Children’s Research Hospital in the form of a $50 million contribution from pharma giant AbbVie – the largest single contribution made to the famed hospital.

December 7, 2018

3 min read

Alex Keown

Drug Development

AbbVie’s Rova-T Sees Another Failure, Casts Doubt on Multi-Billion-Dollar Acquisition

Illinois-based AbbVie halted a Phase III trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.

December 6, 2018

2 min read

Alex Keown

BioMidwest

How Perceptions of High Drug Prices Do Not Necessarily Match Reality

The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.

December 5, 2018

5 min read

Mark Terry

Policy

FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH

The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.

December 5, 2018

3 min read

Mark Terry

Business

BioSpace Feature: A Look at Miracle Drug Humira’s Journey to Proven Efficacy

“Humira is an anti-TNF monoclonal antibody that currently treats Crohn’s disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those, plus other unlisted ailments, total at 15 conditions treated by only one drug.

December 4, 2018

4 min read

Elizabeth Glasure

Biotech Beach

Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.

November 30, 2018

3 min read

Mark Terry

Policy

Many Pharma Directors Also Hold Leadership Roles in Healthcare Nonprofits

Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.

November 30, 2018

3 min read

Alex Keown

Business

New Report Expresses Optimism Over Current State of Alzheimer’s Drug Development

Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.

November 30, 2018

3 min read

Mark Terry

FDA

AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML

AbbVie could be eyeing another potential billion dollars of annual revenue following the accelerated approval of Venclexta for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or who cannot tolerate intensive chemotherapy.

November 26, 2018

2 min read

Alex Keown

JOBS